

Please type a plus sign (+) inside this box →







PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	08/765,108
		Filing Date	March 27, 1997
		First Named Inventor	Monty Krieger
		Group Art Unit	1646
		Examiner Name	Ulm, John D.
Sheet 1 of 13	Attorney Docket Number	MIT 6620 CIP	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		3,625,214		Higuchi	12-07-1974	
		4,244,946		Rivier, et al.	01-13-1981	
		4,305,672		Johnston, et al.	12-15-1981	
		4,316,891		Guillemin, et al.	02-23-1982	
		4,629,784		Stammer	12-16-1986	
		4,789,734		Pierschbacher	12-06-1988	
		4,792,525		Ruoslahti, et al.	12-20-1988	
		4,868,116		Morgan, et al.	09-19-1989	
		4,906,474		Langer, et al.	03-06-1990	
		4,925,673		Steiner, et al.	05-15-1990	
		4,980,286		Morgan, et al.	12-26-1990	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office. <sup>4</sup>	Number <sup>5</sup>	Kind Code <sup>6</sup> (if known)				
		WO	90/05748		Mass. Inst. Tech.	05-31-1990		
		WO	93/01286		Mass. Inst. Tech.	01-21-1993		
		JP	05 192179		Chugai Pharm. Co.	08-03-1993	no translation	
		JP	03 290184		Chugai Pharm. Co	12-19-1991	no translation	

Examine Signature		Date Considered	90-2-24
-------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)  APR 11 2002 PATENT & TRADEMARK OFFICE		Application Number	08/765,108	
		Filing Date	March 27, 1997	
		First Named Inventor	Monty Krieger	
		Group Art Unit	1646	
		Examiner Name	Ulm, John D.	
Sheet	of	13	Attorney Docket Number	MIT 6620 CIP

TECH CENTER 1600/2900

APR 16 2002

RECEIVED

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ABRAMS, et al., "Macrophages in <i>Drosophila</i> embryos and L2 cells exhibit scavenger receptor-mediated endocytosis," <i>Proc. Natl. Acad. Sci. USA</i> 69:16375-16379 (1993).	
		ABUMRAD, et al., "Cloning of a Rat Adipocyte Membrane Protein Implicated in Binding or Transport of Long-chain Fatty Acids That Is Induced during Preadipocyte Differentiation," <i>J. Biol. Chem.</i> 268:17665-17668 (1993).	
		ACTON, et al., "Expression Cloning of SR-BI, a CD36-related Class B Scavenger Receptor," <i>J. Biol. Chem.</i> 269(33):21003-21009 (1994).	
		ACTON, et al., "The Collagenous Domains of Macrophage Scavenger Receptors and Complement Component C1g Mediate Their Similar, But Not Identical, Binding Specificities for Polyanionic Ligands," <i>J. Biol. Chem.</i> 268:3530-3537 (1993).	
		AGRAWAL, et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," <i>Proc. Natl. Acad. Sci. USA</i> 85:7079-7083 (1988).	
		ARAI, et al., "Multiple Receptors for Modified Low Density Lipoproteins in Mouse Peritoneal Macrophages: Different Uptake Mechanisms for Acetylated and Oxidized Low Density Lipoproteins," <i>Biochem. Biophys. Res. Commun.</i> 159:4375-4382 (1989).	
		ARUFFO, et al., "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system," <i>Immunology</i> 84:8573-8577 (1987).	
		ASCH, et al., "Isolation of the Thrombospondin Membrane Receptor," <i>J. Clin. Invest.</i> 79:1054-1061 (1987).	
		ASHKENAS, et al., "Structures and high and low affinity ligand binding properties of murine type I and type II macrophage scavenger receptors," <i>J. Lipid Res.</i> 34:983-1000 (1993).	
		ASKEW, et al., "Molecular Recognition with Convergent Functional Groups. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components," <i>J. Am. Chem. Soc.</i> 111:1082-1090 (1989).	

Examiner's Signature		Date Considered	7-2-97
----------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) 		Application Number	08/765,108
		Filing Date	March 27, 1997
		First Named Inventor	Monty Krieger
		Group Art Unit	1646
		Examiner Name	Ulm, John D.
Sheet 3 of 13	Attorney Docket Number	MIT 6620 CIP	

RECEIVED  
APR 16 2002  
TECH CENTER 1600/2900

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		BALDINI, et al., "Cloning of a Rab3 isotype predominately expressed in adipocytes," <i>Proc. Natl. Acad. Sci. USA</i> 89:5049-5052 (1992).	
		BASU, et al., "Independent Pathways for Secretion of Cholesterol and Apolipoprotein E by Macrophages," <i>Science</i> 219:871-873 (1983).	
		BICKEL, et al., "Rabbit Aortic Smooth Muscle Cells Express Inducible Macrophage Scavenger Receptor Messenger RNA That is Absent from Endothelial Cells," <i>J. Clin. Invest.</i> 90:1450-1457 (1992).	
		BLUME, et al., "Triple helix by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter," <i>Nucl. Acids Res.</i> 20:1777-1784 (1992).	
		BROWN, et al., "Lipoprotein Metabolism in the Macrophage: Implications for Cholesterol Deposition in Atherosclerosis," <i>Annu. Rev. Biochem.</i> 52:223-261 (1983).	
		CALVO, et al., "Identification, Primary Structure, and Distribution of GLA-1, a Novel Member of the CD36/LIMPHII Gene Family," <i>J. Biol. Chem.</i> 268 (25):18929-18935 (1993).	
		CHARRON, et al., "A glucose transport protein expressed predominately in insulin-responsive tissues," <i>Proc. Natl. Acad. Sci. USA</i> 86:2535-2539 (1989).	
		CHEN, et al., "NPXY, a Sequence Often Found in Cytoplasmic Tails, is Required for Coated Pit-mediated Internalization of the Low Density Lipoprotein Receptor," <i>J. Biol. Chem.</i> 265:3116-3123 (1990).	
		GLACKSON, T., et al., "Making antibody fragments using phage display libraries," <i>Nature</i> 352:624-688 (1991).	
		GOONEY, et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene In Vitro," <i>Science</i> 241, 456-459 (1988).	

Examiner's Signature		Date Considered	7-5-97
----------------------	-------------------------------------------------------------------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>Use as many sheets as necessary</p> <p>APR 11 2002</p> <p>PATENT &amp; TRADEMARK OFFICE</p>		Application Number	08/765,108
		Filing Date	March 27, 1997
		First Named Inventor	Monty Krieger
		Group Art Unit	1646
		Examiner Name	Ulm, John D.
Attorney Docket Number	MIT 6620 CIP		
Sheet	4	of	13

**RECEIVED**  
 APR 16 2002  
 TECH CENTER 1600/2900

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<del>CROOKE, "Progress toward oligonucleotide therapeutics: pharmacodynamic properties," <i>FASEB J.</i> 7:533-539 (1993).</del>	
		<del>GULLEN, "Use of Eukaryotic Expression Technology in the Functional Analysis of Cloned Genes," <i>Methods in Enz.</i> 152:684-704 (1987).</del>	
		<del>DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19:2471-2476 (1991).</del>	
		<del>DE RIJKE, et al., "Binding characteristics of scavenger receptors on liver endothelial and Kupffer cells for modified low-density lipoproteins," <i>Biochem. J.</i> 304:69-73 (1994).</del>	
		<del>DOI, et al., "Charged Collagen Structure Mediates the Recognition of Negativity Charged Macromolecules by Macrophage Scavenger Receptors," <i>J. Biol. Chem.</i> 268:2126-2133 (1993).</del>	
		<del>DUVAL-VALENTIN, et al., "Specific inhibition of transcription by triple helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89:504-508 (1992).</del>	
		<del>ELLINGTON, et al., "Selection <i>in vitro</i> of single-stranded DNA molecules that fold into specific ligand-binding structures," <i>Nature</i> 355:850-852 (1992).</del>	
		<del>ENDEMANN, et al., "CD36 is a Receptor for Oxidized Low-Density Lipoprotein," <i>J. Biol. Chem.</i> 268:14814-14816 (1993).</del>	
		<del>FAUST, et al., "Expression of Specific High-Capacity Methylglutamate Transport in a Chinese Hamster Ovary Cell Variant," <i>J. Biol. Chem.</i> 262:1996-2004 (1987).</del>	
		<del>FRASER, et al., "Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor," <i>Nature</i> 364:343-346 (1993).</del>	

Examiner's Signature		Date Considered	7-2-02
----------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	08/765,108
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  APR 11 2002 PATENT & TRADEMARK OFFICE		Filing Date	March 27, 1997
		First Named Inventor	Monty Krieger
		Group Art Unit	1646
		Examiner Name	Ulm, John D.
		Attorney Docket Number	MIT 6620 CIP
Sheet	13		

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		FREEMAN, et al., "Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: Lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein," <i>Proc. Natl. Acad. Sci. USA</i> 88:4931-4935 (1991).	
2		FUKASAWA, et al., "Chinese Hamster Ovary Cells Expressing a Novel Type of Acetylated Low Density Lipoprotein Receptor," <i>J. of Biol. Chem.</i> 270(4):1921-1927 (1995).	
		GOLDSTEIN, et al., "Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition," <i>Proc. Natl. Acad. Sci. USA</i> 76:333-337 (1979).	
		GOLDSTEIN, et al., "Receptor-Mediated Endocytosis of Low Density Lipoprotein in Cultured Cells," <i>Methods Enzymol.</i> 98:241-260 (1993).	
		GREENWALT, et al., "Membrane Glycoprotein CD36: A Review of Its Roles in Adherence, Signal Transduction, and Transfusion Medicine," <i>Blood</i> 80:1105-1115 (1992).	
		GREGORIADIS, G., Chapter 14, "Liposomes," <i>Drug Carriers in Biology and Medicine</i> pp. 287-344 (Academic Press, 1979).	
		GRIGORIEV, et al., "A Triple Helix-forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via inhibition of NF- $\kappa$ B Binding of Interleukin-2 Receptor $\alpha$ -Regulatory Sequence," <i>J. Biol. Chem.</i> 267:3389-3395 (1992).	
		HABERLAND, et al., "Role of the Maleyl-Albumin Receptor in Activation of Murine Peritoneal Macrophages In Vitro," <i>J. Immunol.</i> 142:855-862 (1989).	
		HABERLAND, et al., "Two Distinct Receptors Account for Recognition of Maleyl-Albumin in Human Monocytes during Differentiation In Vitro," <i>J. Clin. Invest.</i> 77:681-689 (1986).	
		HART, et al., "A <i>Drosophila</i> Gene Encoding an Epithelial Membrane Protein with Homology to CD36/LIMP II," <i>J. Mol. Biol.</i> 234:249-253 (1993).	

Examiner's Signature	Date Considered
	10-2-02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	08/765,108
		Filing Date	March 27, 1997
		First Named Inventor	Monty Krieger
		Group Art Unit	1646
		Examiner Name	Ulm, John D.
Attorney Docket Number	MIT 6620 CIP		

13 of



RECEIVED  
APR 16 2002  
TECH CENTER 600/2900

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		HERZ, et al., "Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor," <i>EMBO J.</i> 7:4119-4127 (1988).	
		HOLT, et al., "An Oligomer Complementary to c-myc mRNA Inhibits Proliferation of HL-60 Promyelocytic Cells and Induces Differentiation," <i>Mol. Cell. Biol.</i> 8:963-973 (1988).	
		HORIUCHI, et al., "Scavenger Function of Sinusoidal Liver Cells: Acetylated Low-density Lipoprotein is Endocytosed via a Route Distinct from Formaldehyde-treated Serum Albumin," <i>J. Biol. Chem.</i> 259:53-56 (1985).	
		HUANG, et al., "Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets," <i>Proc Natl. Acad. Sci. USA</i> 88(17):7844-7848 (1991).	
		HUNT, et al., "Characterization and sequence of a mouse hsp70 gene and its expression in mouse cell lines," <i>Gene</i> 87:199-204 (1990).	
		INABA, et al., "Macrophage Colony-stimulating Factor Regulates Both Activities of Neutral and Acidic Cholesteryl Ester Hydrolases in Human Monocyte-derived Macrophages," <i>J. Clin. Invest.</i> 92(2):750-757 (1993).	
		ITAKURA, et al., "Synthesis and use of synthetic oligonucleotides," <i>Ann. Rev. Biochem.</i> 53:323-356 (1984).	
		KABAT, et al., Sequences of Proteins of Immunological Interest, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987).	
		KINGSLEY, et al., "DNA-Mediated Transfer of a Human Gene Required for Low-Density Lipoprotein Receptor Expression and for Multiple Golgi Processing Pathways," <i>Mol. Cell. Biol.</i> 6:2734-2737 (1986).	
		KINGSLEY, et al., "Receptor-mediated endocytosis of low-density lipoprotein: Somatic cell mutants define multiple genes required for express of surface-receptor activity," <i>Proc. Natl. Acad. Sci. USA</i> 81:5454-5458 (1984).	

Examiner's Signature		Date Considered	10-2-97
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)  		Application Number	08/765,108	
		Filing Date	March 27, 1997	
		First Named Inventor	Monty Krieger	
		Group Art Unit	1646	
		Examiner Name	Ulm, John D.	
Sheet	of	13	Attorney Docket Number	MIT 6620 CIP

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
✓		KOBZIK, "Lung Macrophage Uptake of Unopsonized Environmental Particles," <i>J. of Immunol.</i> 155(1):367-376 (1995).
✓		KODAMA, et al., "Type I macrophage scavenger receptor contains $\alpha$ -helical and collagen-like coiled coils," <i>Nature</i> 343:531-535 (1990).
✓		KRIEGER, "Contemplation of Mutations in the LDL Pathway of Receptor-Mediated Endocytosis by Cocultivation of LDL Receptor-Defective Hamster Cell Mutants," <i>Cell</i> 33:413-422 (1983).
✓		KRIEGER, "Molecular Flypaper and atherosclerosis: structure of the macrophage scavenger receptor," <i>Trends Biochem. Sci.</i> 17:141-146 (1992).
✓		KRIEGER, "Molecular Flypaper, Host Defense, and Atherosclerosis," <i>J. Biol. Chem.</i> 268(7):4569-4572 (1993).
✓		KRIEGER, "Reconstitution of the Hydrophobic Core of Low-Density Lipoprotein," <i>Meth. Enzymol.</i> 128:608-613 (1986).
✓		KRIEGER, et al., "Amphotericin B selection of mutant Chinese hamster cells with defects in the receptor-mediated endocytosis of low density lipoprotein and cholesterol biosynthesis," <i>Proc. Natl. Acad. Sci. USA</i> 80:5607-5611 (1983).
✓		KRIEGER, et al., "Isolation of Chinese Hamster Cell Mutants Defective in the Receptor-mediated Endocytosis of Low-Density Lipoprotein," <i>J. Mol. Biol.</i> 150:167-184 (1981).
✓		KRIEGER, et al., "Reconstituted Low-Density Lipoprotein," <i>J. Supra. Struct.</i> 10:467-478 (1979).
✓		KRIEGER, et al., "Structures and Functions of Multiligand Lipoprotein Receptors: Macrophage Scavenger Receptors and LDL Receptor-Related Protein (LRP)," <i>J. Annu. Rev. Biochem.</i> 63:601-637 (1994).

Examiner's Signature		Date Considered	10-1-97
----------------------	-------------------------------------------------------------------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	08/765,108
		Filing Date	March 27, 1997
		First Named Inventor	Monty Krieger
		Group Art Unit	1646
		Examiner Name	Ulm, John D.
		Attorney Docket Number	MIT 6620 CIP
Sheet	13		
<b>OTHER ART - NON PATENT LITERATURE DOCUMENTS</b>			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
		KRIEGER, et al., "Cold Spring Harbor Symposia on Quantitative Biology Vol. LVII, 605-609 (1992).	
		LEWIS, et al., "Automated site-directed drug design: the concept of spacers/skeletons for primary structure generation," <i>Proc. R. Soc. Lond.</i> 236, 125-140 and 141-162 (1989).	
		LOWRY, et al., "Protein Measurement with the Folin-Phenol Reagent," <i>J. Biol. Chem.</i> 193:265-275 (1951).	
2		LUOMA, et al., "Expression of $\alpha_2$ -Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein and Scavenger Receptor in Human Atherosclerotic Lesions," <i>J. Clin. Inv.</i> 93(5):2014-2021 (1994).	
		MAHER, et al., "Inhibition of DNA-Binding Proteins by Oligonucleotide-Directed Triple Helix Formation," <i>Science</i> 245:725-730 (1989).	
		MATSUMOTO, et al., "Human macrophage scavenger receptors: Primary structure, expression, and localization in atherosclerotic lesions," <i>Proc. Natl. Acad. Sci. USA</i> 87:9133-9137 (1990).	
		McKINALLY, et al., "Rational design of antiviral agents," <i>Annu. Rev. Pharmacol. Toxicol.</i> 29:111-122 (1989).	
		MERRIFIELD, "Solid Phase Peptide Synthesis I. The Synthesis of a Tetrapeptide," <i>J. Am. Chem. Soc.</i> 85:2149-2154 (1964).	
		MOESTRUP, et al., "Distribution of the $\alpha_2$ -macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues," <i>Cell Tissue Res.</i> 269:375-382 (1992).	
		MULLIGAN, "The Basic Science of Gene Therapy," <i>Science</i> 260:926-932 (1993).	
Examiner's Signature	Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) 		<b>Complete if Known</b>		
		Application Number	08/765,108	
Sheet	of	13	Attorney Docket Number	MIT 6620 CIP

RECEIVED  
 APR 16 2002  
 TECH CENTER 600/2900

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials <sup>1</sup>	Cite No. <sup>2</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>3</sup>
		<del>NAGELKERKE, et al., "In-Vivo and in-Vitro Uptake and Degradation of Acetylated Low-Density Lipoprotein by Rat Liver Endothelial, Kupffer, and Parenchymal Cells," J. Biol. Chem. 258:12221-12227 (1983).</del>	
		<del>NAITO, et al., "Tissue Distribution Intracellular Localization, and In-Vitro Expression of Bovine Macrophage Scavenger Receptors," Am. J. Pathol. 139:1411-1423 (1991).</del>	
		<del>NARANG, et al., in "Chemical Synthesis of Deoxyoligonucleotides by the Modified Triester Method," Methods Enzymol. 65:610-620 (1980).</del>	
		<del>OCKENHOUSE, et al., Activation of Monocytes and Platelets by Monoclonal Antibodies or Malaria-Infected Erythrocytes Binding to the CD36 Surface Receptor in vitro," J. Clin. Invest. 84:468-475 (1989).</del>	
		<del>OFFENSPERGER, et al., "In-vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides," EMBO J. 12:1257-1262 (1993).</del>	
		<del>OCUENDO, et al., "CD36 Directly Mediates Cytoadherence of Plasmodium falciparum Parasitized Erythrocytes," Cell 58:95-101 (1989).</del>	
		<del>ORSON, et al., "Oligonucleotide inhibition of IL2R<math>\alpha</math> mRNA transcription by promoter region collinear triplex formation in lymphocytes," Nucl. Acids Res. 19:3435-3441 (1991).</del>	
		<del>OTTNAD, et al., "Differentiation of binding sites on reconstituted hepatic scavenger receptors using oxidized low density lipoprotein," Biochem J. 281:745-751 (1992).</del>	
		<del>PEARSON, et al., "Expression cloning of dSR-G1, a class G macrophage-specific scavenger receptor from Drosophila melanogaster," Proc. Natl. Acad. Sci. USA 92:4056-4060 (1995).</del>	
		<del>PENMAN, et al., The Type I and Type II Bovine Scavenger Receptors Expressed in Chinese Hamster Ovary Cells are Trimeric Proteins with Collagenous Triple Helical Domains Comprising Noncovalently Associated Monomers and Cys<sup>63</sup>-Disulfide-linked Dimers," J. Biol. Chem. 266:23985-23993 (1991).</del>	

Examiner's Signature	<i>John D. C...</i>	Date Considered	10-2-92
----------------------	---------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) 		Application Number	08/765,108	
		Filing Date	March 27, 1997	
		First Named Inventor	Monty Krieger	
		Group Art Unit	1646	
		Examiner Name	Ulm, John D.	
Sheet	of	13	Attorney Docket Number	MIT 6620 CIP

OTHER ART - NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		PERRY, et al., "The Use of 3D Modeling Databases for Identifying Structure-Activity Relationships," <u>QSAR: Quantitative Structure-Activity Relationships in Drug Design</u> pp. 189-193 (Alan R. Liss, Inc. 1989).
		PITAS, et al., "Uptake of Chemically Modified Low-Density Lipoproteins In Vivo is Mediated by Specific Endothelial Cells," <u>J. Cell. Biol.</u> 100:103-117 (1985).
		POSTEL, et al., "Evidence that a triplex-forming oligodeoxynucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels," <u>Proc. Natl. Acad. Sci. USA</u> 88: 8227-8231 (1991).
		PREDESGU, et al., "Binding and Transcytosis of Glycoalbumin by the Microvascular Endothelium of the Native Myocardium: Evidence that Glycoalbumin Behaves as a Bifunctional Ligand," <u>J. Cell Biol.</u> 107:1729-1738 (1988).
		RIGOTTI, et al., "The Class B Scavenger Receptors SR-BI and CD36 are Receptors for Anionic Phospholipids," <u>J. Biol. Chem.</u> 270:1-4 (1995).
2		RIGOTTI, et al., "The Class B Scavenger Receptors SR-BI and CD36 Are Receptors for Anionic Phospholipids," <u>J. Biol. Chem.</u> 270(27):16221-16224 (1995).
		RIPKA, "Computers picture the perfect drug," <u>New Scientist</u> 54-57 (June 16, 1988).
		ROHRER, et al., "Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II," <u>Nature</u> 343:570-572 (1990).
		ROUVINEN, et al., "Computer-aided Drug Design," <u>Acta Pharmaceutica Fennica</u> 97:159-166 (1988).
2		SAMBROOK, Fritsch, and Maniatis. <u>Molecular Cloning: A Laboratory Manual</u> , Second Edition, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press (1989) (Table of Contents only).

Examiner's Signature		Date Considered	10-2-92
----------------------	-------------------------------------------------------------------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)  		Application Number	08/765,108	
		Filing Date	March 27, 1997	
		First Named Inventor	Monty Krieger	
		Group Art Unit	1646	
		Examiner Name	Ulm, John D.	
Sheet	of	13	Attorney Docket Number	MIT 6620 CIP

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		SARIN, et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," <i>Proc. Natl. Acad. Sci. USA</i> 85:7448-7451 (1989).	
		SAVILL, et al., "Macrophage-Vitronectin Receptor-CD36 and Thrombospondin Cooperate in Recognition of Neutrophils Undergoing Programmed Cell Death," <i>Chest</i> 99:6S-7S (suppl) (1991).	
		SCHAUB, et al., "Recombinant Human Macrophage Colony-Stimulating Factor Reduces Plasma Cholesterol and Carrageenine Granuloma Foam Cell Formation in Watanabe Heritable Hyperlipidemic Rabbits," <i>Arterioscler. Thromb.</i> 14(1):70-76 (1994).	
		SCHNITZER, et al., "Preferential Interaction of Albumin-binding Proteins, gp36 and gp18, with Conformationally Modified Albumins," <i>J. Biol. Chem.</i> 267:24544-24553 (1992).	
		SGRIVER, et al., Eds., in <i>The Metabolic and Molecular Bases of Inherited Disease</i> , Vol. 11, 7th Ed., pp. 2033, 2066, 2061, New York, McGraw Hill.	
		SEGE, et al., "Characterization of a Family of Gamma-Ray-Induced CHO Mutants Demonstrates that the Id1A Locus is Diploid and Encodes the Low-Density Lipoprotein Receptor," <i>Mol. Cell. Biol.</i> 6:3268-3277 (1986).	
		SEGE, et al., "Expression and regulation of human low-density-lipoprotein receptors in Chinese hamster ovary cells," <i>Nature</i> 307:742-745 (1984).	
		SHAW, et al., "Modified deoxypolynucleotides stable to exonuclease degradation in serum," <i>Nucleic Acids Res.</i> 19:737-750 (1991).	
		SPARROW, et al., "A Macrophage Receptor That Recognizes Oxidized Low-Density Lipoprotein but Not Acetylated Low-Density Lipoprotein," <i>J. Biol. Chem.</i> 264:2599-2604 (1989).	
		STANTON, et al., "A Macrophage Fe Receptor for IgG Is Also a Receptor for Oxidized Low-Density Lipoprotein," <i>J. Biol. Chem.</i> 267:22446-22451 (1992).	

Examiner's Signature		Date Considered	10-7-97
----------------------	-------------------------------------------------------------------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	08/765,108
		Filing Date	March 27, 1997
		First Named Inventor	Monty Krieger
		Group Art Unit	1646
		Examiner Name	Ulm, John D.
		Attorney Docket Number	MIT 6620 CIP

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		STEINBERG, et al., "BEYOND CHOLESTEROL: Modifications of Low-Density Lipoprotein That Increase Its Atherogenicity," <i>N. Engl. J. Med.</i> 320:915-924 (1989).	
		STENT, G.S., et al., <i>Molecular Genetics</i> , pp. 243-249 (1971).	
a		SWIDA, et al., "Glue protein genes in <i>Drosophila virilis</i> : their organization, developmental control of transcription and specific mRNA degradation," <i>Development</i> 108(2):269-280 (1990).	
		SZOSTAK, "In Vitro Genetics," <i>TIBS</i> 19:89-93 (1992).	
		TANDON, et al., "Identification of Glycoprotein IV (CD36) as a Primary Receptor for Platelet-Collagen Adhesion," <i>J. Biol. Chem.</i> 264:7576-7583 (1989).	
		VANDEPOL, et al., "Clinical Applications of Recombinant Macrophage Colony-Stimulating Factor (rhM-CSF)," <i>Biotech. Therap.</i> 2:231-239 (1991).	
		VEGA, et al., "Cloning Sequences and Expression of a cDNA Encoding Rat LIMP-II, a Novel 74-kDa Lysosomal Membrane Protein Related to the Surface Adhesion Protein CD36," <i>J. Biol. Chem.</i> 266:16818-16824 (1991).	
		VIA, et al., "Identification and density-dependent regulation of the AG-LDL-Receptor in normal and transformed bovine aortic endothelial cells (BAEC)," <i>The FASEB J.</i> 6:A371, #2135 (1992).	
		VILLASCHI, et al., "Binding and Uptake of Native and Glycosylated Albumin-Gold Complexes in Perfused Rat Lungs," <i>Microvasc. Res.</i> 32:190-199 (1986).	
		WICKSTROM, et al., "Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA," <i>Proc. Natl. Acad. Sci. USA</i> 85:1028-1032 (1988).	

Examiner's Signature		Date Considered	10-7-97
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	08/765,108
		Filing Date	March 27, 1997
		First Named Inventor	Monty Krieger
		Group Art Unit	1646
		Examiner Name	Ulm, John D.
		Attorney Docket Number	MIT 6620 CIP



OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		YOUNG, et al., "Triple helix formation inhibits transcription elongation in vitro," <i>Proc. Natl. Acad. Sci. USA</i> 88:10023-10026 (1991).	
		ZAMECNIK, et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type-III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA," <i>Proc. Natl. Acad. Sci. USA</i> 83:4143-4146 (1986).	
		ZAMECNIK, et al., "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," <i>Proc. Natl. Acad. Sci. USA</i> 75:280-284 (1978).	
		ZHU, et al., "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice," <i>Science</i> 261:209-211 (1993).	

RECEIVED  
APR 16 2002  
TECH CENTER 1600/2900

Examiner's Signature		Date Considered	10-2-04
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.